The Most Advanced DNA-Encoded
Library Technology

Overcoming the limitations of unbiased screening technologies

Until now, there has been no technology that enabled serendipitous discoveries through unbiased screening by delivering hits fast, cost-effectively and with high quality. Serengen’s breakthrough DNA-Encoded Library (DEL) Technology eliminates the bottlenecks and major cost drivers of established unbiased screening technologies. For the first time, truly druglike DELs can be produced and screened with high speed, cost efficiency and excellent hit quality. 

Limitation-free chemistry
delivers truly druglike hits

We have removed obstacles in DNA-compatible chemistry which led hitherto to mainly non-druglike and intractable hits that were associated with laborious and costly hit follow-up and a high risk of failure. Serengen’s truly druglike tractable hits can be fed directly into lead generation without additional time and cost, which is associated with a low hit-to-lead attrition rate.

Myriads of chemical reactions
create diversity

By removing the limitations of DNA-compatible chemistry, we can perform a multitude of chemical reactions on DNA. This leads to unprecedented flexibility in DEL design and the ability to create diversity through chemical reactions. Our unique encoding strategy allows us to harness the power of chemistry and the creativity of the chemist.

Novel chemical space
addresses new targets

We apply modern screening compound design to DNA-encoded libraries by synthesising the central scaffolds on DNA and decorating them on their exit vectors. By venturing new chemical spaces, you can address new biological targets.

Double
Fidelity

Double purification removes by-products and artefacts and reduces false positives. Concentration adjustment reduces the risk
of false negatives.

Quality
trumps
quantity

Limitation-free chemistry
delivers truly druglike hits

We have removed obstacles in DNA-compatible chemistry which led hitherto to mainly non-druglike and intractable hits that were associated with laborious and costly hit follow-up and a high risk of failure. Serengen’s truly druglike tractable hits can be fed directly into lead generation without additional time and cost, which is associated with a low hit-to-lead attrition rate.

Myriads of chemical reactions
create diversity

By removing the limitations of DNA-compatible chemistry, we can perform a multitude of chemical reactions on DNA. This leads to unprecedented flexibility in DEL design and the ability to create diversity through chemical reactions. Our unique encoding strategy allows us to harness the power of chemistry and the creativity of the chemist.

Novel chemical space
addresses new targets

Double purification removes by-products and artefacts and reduces false positives. Concentration adjustment reduces the risk
of false negatives.

Double
Fidelity

We apply modern screening compound design to DNA-encoded libraries by synthesising the central scaffolds on DNA and decorating them on their exit vectors. By venturing new chemical spaces, you can address new biological targets.

Quality trumps Quantity

Ultra-large DELs are out,
DELs for drug discovery are in!
We only use building blocks that are relevant for medicinal chemistry:
We avoid redundancies and thus reduce costs and time of hit follow-up.
Quality trumps quantity
Ultra-large DELs are out,
DELs for drug discovery are in!
We only use building blocks that are relevant for medicinal chemistry:
We avoid redundancies and thus reduce costs and time of hit follow-up.

ENABLING SERENDIPITY BY REDUCING COSTS AND FAILURE

Addressing novel targets requires novel chemical starting points, However, these are often difficult to find using knowledge-based methods. The most successful approach to identifying hits remains the unbiased screening of large compound collections, which allows invaluable serendipitous discoveries. Traditionally, this has been done through high- throughput screening (HTS), which is resource, cost and time-intensive and requires sophisticated infrastructure. DNA-encoded library (DEL) technology can bridge this gap. It can be fast, inexpensive and requires only a lean infrastructure.

However, traditional DELs mostly contain non-druglike compounds, Poor hit quality typically leads to failures in lead generation or optimisation. This is a major problem because hit quality is the most important success factor in early drug discovery.

At Serengen, we overcome the limitations of traditional DELs by addressing three key points: (I) chemistry, (II) design, and (III) approach.

As a result, our technology increases the probability
of serendipitous discoveries with high hit quality and
reduces costs and failure in early drug discovery.

Talk to
our experts!

+49 (0)231 999 50 902

Contact us for a brainstorming session.
We are happy to answer any question!

Talk to
our experts!

+49 (0)231 999 50 902

Contact us for a brainstorming session.
We are happy to answer any question!

*Required

I agree that the information I supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679.